Publications by authors named "Andrea Bagameri"

Claim this Profile
R
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Alexander B Olawaiye, Laurence Gladieff, David M O'Malley, Jae-Weon Kim, Gabriel Garbaos

Lancet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
Ignace Vergote, Larry J Copeland, Toon Van Gorp, Annouschka Laenen, Giovanni Scambia

Eur J Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, Elsa Kalbacher, Andrea Bagaméri

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.
Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, Erin Bishop, Anita Chudecka-Głaz

J Gynecol Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The treatment of ovarian cancer. Recommendation of the Hungarian Society of Gynaecologic Oncologists].
Zoltán Novák, Andrea Bagaméri, Szabolcs Máté, Ildikó Vereczkey, Erika Tóth

Magy Onkol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
David M O'Malley, Maryna Neffa, Bradley J Monk, Tamar Melkadze, Marilyn Huang, Andrea Bagameri

J Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Results of docetaxel therapy in patients with relapsed ovarian cancer].
Ottó Lehoczky, László Thurzó, Andrea Bagaméri, Zsuzsanna Sárosi, János Udvary

Magy Onkol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does increasing the steroid dose enhance the efficacy of the antiemetic combination of granisetron and methylprednisolone in gynecologic cancer patients--a randomized study.
Ottó Lehoczky, János Udvary, Andrea Bagaméri, Tamás Pulay

Eur J Obstet Gynecol Reprod Biol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].
Ottó Lehoczky, Andrea Bagaméri, Tamás Pulay

Orv Hetil· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
O Lehoczky, Andrea Bagaméri, J Udvary, T Pulay

J Obstet Gynaecol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Early results of topotecan therapy in patients with recurrent ovarian cancer].
Ottó Lehoczky, Andrea Bagaméri, Gyózó Lehoczky, Tamás Pulay

Orv Hetil· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis